Opaleye Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Opaleye Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-25,000	Closed	-$1.71M	–	63
2021 Q1	$1.71M	Sell	25,000 -89,000	-78%	-$7.2M	0.25%	50
2020 Q4	$9.77M	Sell	114,000 -350	-0.3%	-$29.7K	1.28%	23
2020 Q3	$7.43M	Hold	114,350	–	–	1.45%	28
2020 Q2	$8.36M	Buy	+114,350	New	+$6.09M	1.69%	22
2020 Q1	–	Sell	-165,000	Closed	-$8.98M	–	58
2019 Q4	$8.98M	Buy	165,000 +5,000	+3%	+$248K	1.76%	25
2019 Q3	$6.67M	Buy	160,000 +10,000	+7%	+$422K	2.41%	21
2019 Q2	$6.57M	Buy	+150,000	New	+$8.46M	2%	22

Other funds holding BHVN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Opaleye Management's BHVN Position: Q2 2021 in Review

Opaleye Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2021, closing a stake of 25,000 shares — an estimated $1.71M sold.

Opaleye Management first reported a position in BHVN in Q2 2019 and held it in 7 quarters. The position peaked at $9.77M in Q4 2020. 223 funds tracked by Wall St. Rank hold BHVN as of Q2 2021.

Opaleye Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2021 after selling out during the quarter.
Opaleye Management sold 25,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2021, an estimated $1.71M.
Opaleye Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 7 quarters.
Opaleye Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $9.77M in Q4 2020.
223 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2021.

Based on Opaleye Management's 13F filing for Q2 2021, filed 16 Aug 2021.